BioNTech’s Dynasty-Breast02 P3 Trial Met Primary Endpoint

BioNTech said DYNASTY-Breast02 met its primary endpoint with a statistically significant but modest PFS improvement; OS data were immature. A higher ILD rate, mostly Grade 1-2 with some severe/fatal cases, was reported. Companies will review next steps.Material DetailsContext by AI AnalystThis is a…